Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome

European Journal of Endocrinology

Volumn 159, Issue 3, 2008, Pages 225-232

  Escobar Morreale, Héctor F ^a   Botella Carretero, José I ^a   Martínez García, Ma Ángeles ^a   Luque Ramírez, Manuel ^a   Álvarez Blasco, Francisco ^a   San Millán, José L ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; OSTEOPROTEGERIN; OSTEOCLAST DIFFERENTIATION FACTOR; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TNFSF11 PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; BODY MASS; CASE CONTROL STUDY; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; BLOOD PRESSURE; DOWN REGULATION; HIRSUTISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; BLOOD PRESSURE; CASE-CONTROL STUDIES; DOWN-REGULATION; FEMALE; GONADAL STEROID HORMONES; HIRSUTISM; HUMANS; OBESITY; OSTEOPROTEGERIN; POLYCYSTIC OVARY SYNDROME; RANK LIGAND; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 53249101837     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-08-0107     Document Type: Article

References (55)

1. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S & Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. Journal of Clinical Endocrinology and Metabolism 2000 85 2434-2438.
2. Escobar-Morreale HF, Luque-Ramirez M & San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocrine Reviews 2005 26 251-282.
3. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM & Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. Journal of Clinical Endocrinology and Metabolism 2001 86 2453-2455.
4. Escobar-Morreale HF, Calvo RM, Villuendas G, Sancho J & San Milian JL. Association of polymorphisms in the interleukin 6 receptor complex with obesity and hyperandrogenism. Obesity Research 2003 11 987-996.
5. Villuendas G, San Millan JL, Sancho J & Escobar-Morreale HF. The -597 G→A and -174 G→C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. Journal of Clinical Endocrinology and Metabolism 2002 87 1134-1141.
6. Peral B, San Millan JL, Castello R, Moghetti P & Escobar-Morreale HF. The methionine 196 arginine polymorphism in exon 6 of the TNT receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism. Journal of Clinical Endocrinology and Metabolism 2002 87 3977-3983.
7. Escobar-Morreale HF, Calvo RM, Sancho J & San Milian JL. TNF-α and hyperandrogenism: a clinical, biochemical, and molecular genetic study. Journal of Clinical Endocrinology and Metabolism 2001 86 3761-3767.
8. Escobar-Morreale HF, Botella-Carretero JI, Villuendas G. Sancho J & San Millan JL. Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. Journal of Clinical Endocrinology and Metabolism 2004 89 806-811.
9. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB & Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. New England Journal of Medicine 2004 350 1387-1397.
10. Frishman WH. Biologic markers as predictors of cardiovascular disease. American Journal of Medicine 1998 104 18S-27S.
11. Fernandez-Real JM & Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocrine Reviews 2003 24 278-301.
12. Dandona P, Aljada A, Chaudhuri A, Mohanty P & Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation, Circulation 2005 111 1448-1454.
13. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R & Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 89 309-319.
14. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F. Morinaga T & Higashio K. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochemical and Biophysical Research Communications 1997 234 137-142.
15. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N & Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. PNAS 1998 95 3597-3602.
16. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC & Young PR. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. Journal of Biological Chemistry 1998 273 14363-14367.
17. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA & Giachelli CM. Osteoprotegerin is an alpha vbeta 3-induced, NF-κ B-dependent survival factor for endothelial cells. Journal of Biological Chemistry 2000 275 20959-20962.
18. Scatena M & Giachelli C. The alpha(v)beta3 integrin, NF-κB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. Trends in Cardiovascular Medicine 2002 12 83-88.
19. Schoppet M, Preissner KT & Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 549-553.
20. Ugur-Altun B, Altun A, Gerenli M & Tugrul A. The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity. Diabetes Research and Clinical Practice 2005 68 217-222.
21. Holecki M, Zahorska-Markiewicz B, Janowska J, Nieszporek T, Wojaczynska-Stanek K, Zak-Golab A & Wiecek A. The influence of weight loss on serum osteoprotegerin concentration in obese perimenopausal women. Obesity 2007 15 1925-1929.
22. Zawadzki JK & Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Polycystic Ovary Syndrome, pp 377-384. Eds A Dunaif, JR Givens, FP Haseltine & GR Merriam, Boston: Blackwell Scientific Publications, 1992.
23. Escobar-Morreale HF, Sanchon R & San Millan JL. A prospective study of the prevalence of nonclassic congenital adrenal hyperplasia (NCAH) among women presenting with hyperandrogenic symptoms and signs. Journal of Clinical Endocrinology and Metabolism 2008 93 527-533.
24. Hatch R, Rosenfield RL, Kim MH & Tredway D. Hirsutism: implications, etiology, and management. American Journal of Obstetrics and Gynecology 1981 140 815-830.
25. Bakhireva LN, Laughlin GA, Bettencourt R & Barrett-Connor E. Does osteoprotegerin or receptor activator of nuclear factor-kappaB ligand mediate the association between bone and coronary artery calcification? Journal of Clinical Endocrinology and Metabolism 2008 93 2009-2012.
26. Escobar-Morreale HF, Serrano-Gotarredona J, García-Robles R, Sancho J & Varela C. Lack of an ovarian function influence on the increased adrenal androgen secretion present in women with functional ovarian hyperandrogenism. Fertility and Sterility 1997 67 654-662.
27. Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J & San Millan JL. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. Journal of Clinical Endocrinology and Metabolism 2005 90 6364-6369.
28. Vermeulen A, Verdonck L & Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism 1999 84 3666-3672.
29. Matsuda M & DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999 22 1462-1470.
30. Sandberg WJ, Yndestad A, Oie E, Smith C, Ueland T, Ovchinnikova O, Robertson AK, Muller F, Semb AG, Scholz H, Andreassen AK, Gullestad L, Damas JK, Froland SS, Hansson GK, Halvorsen B & Aukrust P. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 857-863.
31. Kiechl S, Schett G, Schwaiger J, Seppi K, Eder P, Egger G, Santer P, Mayr A, Xu Q & Willeit J. Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation 2007 116 385-391.
32. Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM & Weissberg PL. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circulation Research 2000 87 1055-1062.
33. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, Schwartz SM, Giachelli CM & Rosenfeld ME. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 2117-2124.
34. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ & Simonet WS. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes and Development 1998 12 1260-1268.
35. Price PA, June HH, Buckley JR & Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 1610-1616.
36. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K & Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002 106 1192-1194.
37. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B & Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. Journal of Clinical Endocrinology and Metabolism 2003 88 1024-1028.
38. Avignon A, Sultan A, Piot C, Mariano-Goulart D, Thuan Dit Dieudonne JF, Cristol JP & Dupuy AM. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care 2007 30 2934-2939.
39. Ziegler S, Kudlacek S, Luger A & Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 2005 182 175-180.
40. Guldiken B, Guldiken S, Turgut B, Turgut N, Demir M, Celik Y, Arikan E & Tugrul A. Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct. Thrombosis Research 2007 120 511-516.
41. Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, Jain T, Gruntmanis U, McGuire DK & de Lemos JA. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). American Journal of Cardiology 2007 99 513-518.
42. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, Herlitz J, Aukrust P, Hartford M & Caidahl K. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. Journal of the American College of Cardiology 2008 51 627-633.
43. Zauli G, Corallini F, Bossi F, Fischetti F, Durigutto P, Celeghini C, Tedesco F & Secchiero P. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007 110 536-543.
44. Mangan SH, Campenhout AV, Rush C & Golledge J. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angio-poietin-2. Cardiovascular Research 2007 76 494-505.
45. Saika M, Inoue D, Kido S & Matsumoto T. 17β-Estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology 2001 142 2205-2212.
46. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC & Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999 140 4367-4370.
47. Khosla S, Atkinson EJ, Dunstan CR & O'Fallon WM. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. Journal of Clinical Endocrinology and Metabolism 2002 87 1550-1554.
48. Hofbauer LC, Hicok KC, Chen D & Khosla S. Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. European Journal of Endocrinology 2002 147 269-273.
49. Chen Q, Kaji H, Kanatani M, Sugimoto T & Chihara K. Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells. Hormone and Metabolic Research 2004 36 674-678.
50. Szulc P, Hofbauer LC, Heufelder AE, Roth S & Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. Journal of Clinical Endocrinology and Metabolism 2001 86 3162-3165.
51. Kim SM, Lee J, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS & Choi KM. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clinical Endocrinology 2005 63 594-598.
52. Indridason OS, Franzson L & Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporosis International 2005 16 417-423.
53. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K & Yamada Y. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research 1999 14 518-527.
54. Noyan V, Yucel A & Sagsoz N. The association of bone mineral density with insulin resistance in patients with polycystic ovary syndrome. European Journal of Obstetrics, Gynecology and Reproductive Biology 2004 115 200-205.
55. Good C, Tulchinsky M, Mauger D, Demers LM & Legro RS. Bone mineral density and body composition in lean women with polycystic ovary syndrome. Fertility and Sterility 1999 72 21-25.